Indian stocks: Visit www.stage2stocks.com →

SOPHiA GENETICS SA

Stage 2 · Advancing · week 24

As of Oct 22, 2026, SOPHiA GENETICS SA is in Stage 2, the uptrend phase, now in week 24 (since May 5, 2026). It closed at $7.05, 21.0% below its 52-week high and above its 200-day average, which is rising.

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. More about the company

$7.05
-4.08% today
$600M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 16 in Health Information Services · #1 of 272 in Health Care

Is SOPH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 14w
S4 26w
S4 14w
S2 28w
S2 24w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 2w → S4 8w → S1 7w → S2 14w → S3 2w → S2 4w → S3 4w → S2 2w → S3 6w → S4 26w → S1 8w → S4 14w → S1 6w → S2 28w → S3 9w → S2 24w current
Total tracked: 165 weeks across 16 stage runs.

SOPH among Health Information Services5th of 41 by relative strength

All 41 →
Stocks in Health Information Services ranked by relative strength, with stage and one-month change
#StockStageRS1M
1AMWLStage 2 · wk 2597+7.4%
2HNGEStage 2 · wk 2096+19.1%
3BTSGStage 3 · wk 894+9.1%
4NRCStage 3 · wk 493−0.1%
5SOPHStage 2 · wk 2491−12.7%
6HTFLStage 2 · wk 1087+17.0%
7HSTMStage 2 · wk 1777+20.3%
8OMCLStage 4 · wk 1070+12.5%
vs 52W High
-21.0%
$3.89 lo$8.92 hi
21.0% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 24
1w13w26w
Week 24, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
20.0%
200 DMA: $5.87 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.56x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-12.7%
3M
+23.3%
6M
+44.8%
YTD
+51.0%
1Y
+67.9%
Scan Membership
Breakout Watch
Latest: 2024-06-13
4 appearances in last 60 days. First seen: 2023-03-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 24 · Vol 0.56x
2026-10-21S2
Wk 24 · Vol 0.99x
2026-10-20S2
Wk 24 · Vol 1.02x
2026-10-19S2
Wk 24 · Vol 0.81x
2026-10-16S2
Wk 23 · Vol 1.47x
2026-10-15S2
Wk 23 · Vol 2.91x
2026-10-14S2
Wk 23 · Vol 0.60x
2026-10-13S2
Wk 23 · Vol 0.43x
2026-10-12S2
Wk 23 · Vol 0.77x
2026-10-09S2
Wk 22 · Vol 0.53x
2026-10-08S2
Wk 22 · Vol 0.82x
2026-10-07S2
Wk 22 · Vol 0.71x
Moving averages & range
50 DMA
$7.90
200 DMA
$5.87
52W High
$8.92
52W Low
$3.89
5D Low
$6.49
Resistance levels (recent highs)
20d High
$8.49
60d High
$8.92
120d High
$8.92
250d High
$8.92
Next resistance
+20.4%
to 20d High
ROE
-101.2%
Profit margin -93.9%
Dividend Yield
0.00%
P/B 7.2

SOPHiA GENETICS SA: quick answers

What stage is SOPHiA GENETICS SA in?

As of Oct 22, 2026, SOPHiA GENETICS SA (SOPH) is in Stage 2, the uptrend phase. It entered Stage 2 on May 5, 2026 and is in week 24. What the four stages mean

Is SOPHiA GENETICS SA in an uptrend?

Yes. SOPHiA GENETICS SA is in a Stage 2 uptrend. It trades 20.0% above its 200-day average, which is rising.

How far is SOPHiA GENETICS SA from its 52-week high?

SOPHiA GENETICS SA closed at $7.05 on Oct 22, 2026, 21.0% below its 52-week high of $8.92. Its 52-week low is $3.89.

How has SOPHiA GENETICS SA performed over the past year?

As of Oct 22, 2026, SOPHiA GENETICS SA is up 67.9% over the past year and up 51.0% so far in 2026.

Which sector and industry is SOPHiA GENETICS SA in?

SOPHiA GENETICS SA is in the Health Information Services industry, part of the Health Care sector.

About this companyHealth Care· Health Information Services

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.